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Abstract 
Objective - To establish the aqueous humor flow rate in normal cats via 
fluorophotometry, utilizing a noninvasive method previously established in other species and to 
evaluate the effect of topical 2% dorzolamide on aqueous humor flow rate and intraocular 
pressure (IOP) in normal cats. 
Animals - 20 clinically normal domestic shorthair cats. 
Procedures – Topical administration of 10% sodium fluorescein was performed using a 
3-drop protocol to establish its use in this species.  Aqueous flow was measured using 
fluorophotometry in the right and left eyes.  The subjects were then divided into 2 groups:  the 
first received topical 2% dorzolamide (Trusopt®) and the second received topical artificial tear 
solution (control).  The study was divided into two phases:  a 3 day acclimation phase (no 
treatments given) and a 5 day treatment phase (treatments given three times daily).  IOP 
measurements were taken at 7am, 10am, 1pm, 5pm, and 9pm throughout all phases of the study.  
Fluorophotometry was performed to measure the aqueous flow rate just prior to and at the end of 
the treatment phase (days 3 and 9 respectively).   
Results - The calculated aqueous humor flow rate for normal cats in the right, left, and 
both eyes was 5.94 ± 2.30 μl/min, 5.05 ± 2.06 μl/min, and 5.51 ± 2.21 μl/min, respectively.  No 
significant differences were noted between the right and left eyes.  In the dorzolamide group, the 
average flow rate during treatment (3.47 + 1.50 µl/min ) was significantly lower than prior to 
treatment (5.9 + 2.20 µl/min)(P < 0.001).  The mean IOP during treatment (11 + 3 mmHg) was 
significantly lower than the mean IOP prior to treatment (15 + 3 mmHg)(P <  0.001).  In the 
control group, there were no significant differences in aqueous humor flow or IOP values before 
or during treatment. 
Conclusions - The technique utilized for this study met the standard for accurate 
fluorophotometric calculation of aqueous humor flow.  The average aqueous humor flow rate for 
normal cats calculated in this study was 5.51 ± 2.21 μl/min.  Topical 2% dorzolamide 
significantly lowers aqueous humor flow (a 41% reduction) and IOP (a 26% reduction) in normal 
cats. 
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Chapter 1 - Literature Review 
 Aqueous Humor Dynamics 
 Aqueous Humor 
The aqueous humor is a transparent fluid produced within the eye that serves several 
important roles vital in maintaining proper ocular function.  First and foremost it is a pellucid 
medium filling the anterior and posterior chambers and has a refractive index of 1.33332, 
allowing for a clear pathway for light entering the eye.
1
  It is a relatively acellular, low protein 
fluid, composed of organic and inorganic compounds necessary to nourish avascular structures 
within the eye, such as the cornea and lens, for which it also serves as a conduit for waste 
removal.
2,3
  The specific levels of these compounds are species specific, and rely on a stout 
barrier between the aqueous humor and the blood to prevent equilibration with the systemic 
circulation.
4
  This blood-aqueous barrier is created by tight junctions in the ciliary body 
epithelium, the iridal vascular endothelium, and the posterior pigmented epithelium of the iris.
5
  
The aqueous humor also preserves the appropriate alignment of ocular structures necessary for 
vision by maintaining the intraocular pressure (IOP) within the eye.
1
 
 Aqueous Humor Production 
Aqueous humor is produced by the nonpigmented ciliary body epithelium on the interior 
surface of the ciliary processes located in the pars plicata region of the ciliary body.
6
  Three 
mechanisms combine to form the aqueous humor found in the eye; they are: diffusion, 
ultrafiltration, and active secretion.  Diffusion occurs when solutes move down a concentration 
gradient from a region of high concentration to low concentration.  Carbohydrates and lipid-
soluble compounds enter the aqueous humor via this process.
4
  Ultrafiltration allows for the 
movement of plasma from an area of high hydrostatic pressure to an area of lower pressure.  It is 
by this method that blood plasma is deposited into the ciliary process stroma from the ciliary 
capillaries, passing thorough fenestrations in the capillary endothelium.
2
  These first two 
processes create the pool of materials within the ciliary stroma that is then ready to cross the 
blood-aqueous barrier at the nonpigmented ciliary body epithelium and enter the posterior 
2 
 
chamber.
1
Active secretion represents the most important process in the formation of the aqueous 
humor.
4
  It allows for the accumulation of important ionic compounds at higher levels within the 
aqueous humor, creating a gradient for the diffusion of water and other compounds.  Active 
secretion occurs across the functional syncytium of the pigmented and nonpigmented ciliary 
body epithelium.
2
  Requiring ATP dependent pumps, the secretion that occurs is driven primarily 
by sodium-potassium-ATPase and carbonic anhydrase, though other active transport mechanisms 
exist.
1
  Sodium, bicarbonate, chloride, and ascorbate are examples of compounds that are 
actively secreted into the posterior chamber.
4
 
 Aqueous Humor Drainage 
The aqueous builds in the posterior chamber and then flows anteriorly, through the pupil, 
and into the anterior chamber.  In the anterior chamber, convection currents (driven by warmer 
temperatures at the iris face and cooler temperatures of the cornea) circulate the aqueous until it 
drains via passive flow following one of two routes:  1) via conventional outflow, through the 
iridocorneal angle, past the trabecular meshwork and into species-specific vascular channels that 
direct aqueous to the systemic circulation, or 2) via uveoscleral outflow, diffusion across the iris 
and ciliary body and into the suprachoroidal space.
1
  The specific amount that is drained by each 
route is dictated by individual species.  In humans, the outflow of aqueous is shared more or less 
equally between the two routes.
1
  In dogs, studies indicate approximately 15% of the aqueous 
humor is drained via the uveoscleral route, whereas in cats uveoscleral flow represents only 3% 
of total drainage.
4,7
 
 Aqueous Humor Flow 
In the normal eye, the flow of aqueous is dictated by the rate of formation and the rate of 
drainage of the aqueous humor.
8
  This balance between production and drainage determines the 
pressure found within the eye itself, or IOP (10-20 mmHg in most species).
4
  The rate of 
formation of the aqueous is relatively constant as the bulk of its production is dictated by active 
secretion and resultant diffusion.  Ultrafiltration, a smaller component process of aqueous 
production, does not have a large enough contribution to have a great effect on the overall 
production rate.
9
  The rate of drainage of the aqueous humor is dependent upon the resistance to 
flow present at the outflow channels.  Along the conventional outflow path, this resistance is 
both pressure dependent, by the venous pressure of the collecting vessels, and pressure 
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independent, by the membranes of vascular collecting channels and extracellular matrix.
4
  
Interestingly, drainage along the uveoscleral outflow path is independent of IOP; with flow 
resistance created by the tissues that line the outflow pathways, similar to lymphatic drainage.
1,10
  
The resultant flow rate has been determined in a variety of species using various methods, with 
aqueous flow rate averages of 2.5 μl/min in humans,11-16 3 μl/min in rabbits,17-21 5 μl/min in 
dogs,
22-25
 and 6 μl/min in cats.26-29 
 Evaluation of Aqueous Humor Flow 
 Invasive Techniques 
The aqueous humor flow rate has been studied extensively over the last 70 years.  A 
variety of techniques have been utilized to assess both path of aqueous drainage and the rate of 
aqueous humor flow (assessed via drainage and production).  Initial attempts at determination of 
the aqueous humor flow path and rate involved direct cannulization and perfusion, the injection 
of various tracer compounds, or a combination thereof.  These experiments were highly invasive, 
at times requiring the ligation of renal arteries,
30
 and utilized nonhuman test subjects for 
completion, primarily rabbits, primates, and cats. 
 Cannulization 
Direct cannulization of the eye allowed investigators to perfuse the anterior chamber in 
an attempt to recreate various normal and abnormal pressure scenarios.  Studies utilized either 
constant pressure perfusion:  a constant IOP is maintained via perfusate injected at a constant 
rate or predetermined intervals; or constant rate perfusion:  the perfusate is injected at a 
determined rate, allowing for fluctuations of IOP.
4
  Many of these studies were designed to 
evaluate the facility of outflow, or the maximum ability for aqueous to exit via the anterior 
chamber; however, manipulation of the various experimental setups also allowed for estimations 
of aqueous production.
7,10,31-33
  In 1954, Bárány and Scotchbrook developed the two-step 
constant pressure perfusion technique:  an eye is perfused for a few minutes at two different 
levels (2-3 mmHg and 8-10 mmHg above baseline) and the resultant flow rates are analyzed.
34
  
This is the most widely used procedure in perfusion studies today.
4,32
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 Tracer Compounds 
Many perfusion studies were combined with the application of radioactively labeled 
tracers.  A host of various compounds were utilized by a multitude of researchers, to both 
evaluate aqueous humor flow and also address other important aspects of aqueous humor 
dynamics.  These compounds were introduced into the eye either through direct injection or after 
being injected into the systemic circulation and allowed to enter the aqueous through natural 
transport systems.  Tracer compounds were also used without direct perfusion in order to prevent 
the disruption of natural aqueous flow, but were still considered invasive due to the unknown 
effect many of the compounds would have on the patient.  The compounds used varied widely 
and were designed to meet the specifications for the study goals of each researcher.  In their 
studies O’Rourke and Macri, Macri et al., and Bill used radioactively labeled particles, such as 
albumin and inulin, as they are large, easy to measure, and readily available.
35-37
  Langham used 
cysteine and ascorbic acid, already found in high levels in the aqueous humor, to concurrently 
investigate both the aqueous flow rate and properties of aqueous formation.
30
  A series of 
compounds (sodium, p-aminohippurate, sucrose, ethyl alcohol, and propyl thiourea, p-amino 
hippuric acid, rayopake, diodrast) have been chosen for their different physiologic properties to 
investigate the different characteristics of aqueous formation and drainage.
38,39
  Through these 
studies, not only have aqueous flow rates been calculated, but they all appeared to decrease at 
this surprisingly similar rate, indicating aqueous humor was removed in a bulk, nonspecific 
manner.
38
 
While some researchers were establishing aqueous flow rates, other researchers were 
concurrently evaluating the location of these aqueous outflow routes using similar methods.  In 
1942, Ascher first documented the flow of aqueous into ocular vasculature, thus allowing a first 
glimpse into the conventional route of aqueous outflow.
40
  That same year, Troncoso’s 
investigations into rabbits revealed these vessels were separated from the anterior chamber, only 
by the trabecular meshwork.
41
  Building upon these discoveries, investigators utilized injected 
tracers (
131
I-labeled albumin and 
14
C-labeled inulin) and the direct cannulization of intrascleral 
vessels to describe the basic conventional pathway for bulk aqueous flow.
35,37
  In 1965, Bill’s 
continued investigations of outflow pathways using labeled albumin led to the discovery of the 
uveoscleral route for aqueous drainage.
7,10
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 Non-Invasive Techniques 
As continued progress was made in the evaluation of the aqueous humor flow, 
researchers’ desire to apply this knowledge to human subjects demonstrated the need for a 
noninvasive method of flow evaluation.  Initially, a technique was developed that allowed for 
tonography to be used to calculate the facility of aqueous outflow.
42,43
  The calculated outflow 
facility was then applied to the Goldmann equation to determine aqueous flow:   
F = (Pi – Pe) x C,  
where F = rate of aqueous humor formation, Pi = the IOP, Pe  = the episcleral venous 
pressure, and C is the facility of outflow measured tonographically.
43
  After Bill’s discovery of 
the uveoscleral outflow pathway, the equation was modified to: 
 F = (Pi – Pe) x C + U,  
where U = uveoscleral outflow.
43
  Due to the development of more accurate methods of 
determining aqueous humor flow, tonography has largely been replaced as a measurement of 
aqueous humor production; however, it remains a commonly used flow measurement in 
determining conventional outflow facility and uveoscleral outflow.
18,20,27,44-52
 
Starting as early as 1950, the concentration of fluorescein in the anterior chamber was 
used to investigate aqueous humor flow.
16
  Initial attempts utilized systemic administration of 
fluorescein that, when combined with serial slit lamp evaluations and the collection of blood 
samples, could be applied to an exceedingly complicated mathematical equation to obtain flow 
estimation.  A few years later, the concept of topical administration of fluorescein was 
introduced, finally yielding a noninvasive method of flow investigation.
53,54
  This early 
technique, however, was hampered by the lack of an objective, quantitative measurement device 
for fluorescein concentration calculation.  In 1963, Maurice unveiled a new fluorophotometer, 
which, along with a practical method of measurement introduced by Maurice and Jones three 
years later, has become the staple of aqueous humor flow measurement today.
11,55
 
 Fluorophotometry 
 Concept 
Fluorophotometry is the quantified measurement of light emitted by sodium fluorescein 
after stimulation by blue light.  It can be used to evaluate the concentration of fluorescein in 
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various transparent media and is most commonly used to evaluate intraocular fluorescein 
concentrations in either the aqueous or vitreous humors.  Fluorescein can be introduced 
systemically or topically and can be utilized to investigate the blood aqueous barrier,
56-60
 the 
blood retinal barrier,
61
 corneal endothelial permeability,
14,62,63
 tear flow dynamics,
64,65
 and 
aqueous humor flow calculations.
16
 
The computerized scanning electronic fluorophotometer was introduced in 1963 by 
Maurice as a new, quantitative method for the evaluation of sodium fluorescein concentrations in 
the eye.
55
  Though more advanced models have been created, the basic principle remains the 
same.
12
  The machine is essentially a modified slit lamp with a fiber optic probe that emits a 
focused beam of blue (480nm) light.  A barrier filter allows only the green (520nm) light that 
indicates peak fluorescence to be evaluated, thereby reducing the effect of scatter.  The digital 
radiometer then compares the emitted fluorescein to known fluorescein curves to determine the 
concentration seen at each measured point.
66
  These concentrations are then monitored over a set 
period of time.  This decline of fluorescein concentration is then attributed to the drainage of the 
fluorescein-aqueous mix and further dilution as it is replaced by new aqueous humor that is 
being produced.  The aqueous humor flow calculation given by fluorophotometry is an 
estimation of aqueous outflow of both the conventional and uveoscleral routes.
52
 
 Equation Derivation 
Maurice and Jones established the basic calculations utilized for fluorophotometric 
evaluation of aqueous flow shortly after the introduction of the new fluorophotometer.
11
  Their 
evaluation is based upon three assumptions:  a) the topically applied sodium fluorescein is 
homogenously distributed throughout the cornea and aqueous humor during the measured time 
points; b) after the initial sodium fluorescein application, no further sodium fluorescein is applied 
to the cornea; and c) the corneal and aqueous humor sodium fluorescein concentrations decrease 
at the same rate over the course of the measured time points.  Utilizing these assumptions, the 
basis for fluorophotometric calculation relies on 3 equations:
11
 
 
(1)  dCc/dt = kc.ca(Ca- Cc),  
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where kc.ca is the transfer coefficient from the cornea to the aqueous, Ca is the effective 
aqueous fluorescein concentration, and Cc is the effective corneal concentration of fluorescein; 
 
 (2)  dCa/dt = KoCa + ka.ca(Cc– Ca), 
 
where Ko is the anterior chamber loss coefficient and ka.ca is the transfer coefficient from 
the aqueous to the cornea; and 
 
 (3)  dmt/dt = - CaVaKo, 
 
where mt is the total mass of fluorescein and Va is the volume of aqueous humor. 
Before continuing with further mathematical derivation, it is important to point out that 
several assumptions have been made to make these equations possible.  For the first equation, it 
is assumed that all fluorescein present within the cornea is exchanged with the aqueous humor 
and that no exchange occurs between the cornea and limbal blood vessels.  For the second 
equation, it is assumed that the concentration of fluorescein in the blood is negligible.  And for 
the third, that fluorescein is lost by the cornea to the aqueous humor alone. 
Because fluorophotometric evaluation occurs at steady state, equation (2) can be further 
reduced to: 
 (2)  dCa/dt = KoCa 
 
Since we assume that the concentrations of the cornea and aqueous will be decreasing at 
the same rate at steady state, and thus the rate of fluorescein egress from the cornea to the 
aqueous and the aqueous to the blood stream are the same, we can plot the three equations and 
their slopes are represented by the differential expressions:  dln mt/dt, dln Cc/dt, and dln Ca/dt. 
(Figure 1.1) 
 
 
 
 
 
8 
 
Figure 1.1  Plotted Equations of Fluorescein Egress 
 
The terminal slope of these curves are all the same and is represented by the equation: 
 
 (4)  A = -VaCaKo/mt 
  
In 1978, Yablonski et al. introduced a modification to the original calculations to avoid 
direct measurement of mt.
13
  Because the total mass of fluorescein is equal to the mass of 
fluorescein in the anterior chamber and the cornea, then mt = VaCa.+ VcCc, which means that: 
 
(4) A = -VaCaKo/(VaCa.+ VcCc) 
 
By solving for Kothis equation can be further modified to: 
 
(4)  Ko= -A x (1 + [VcCc/VaCa]) 
 
Before completing the final aqueous humor flow equation, two correction factors have 
been introduced to assure more exact aqueous humor flow rates, both of which are inherent to 
the fluorophotometric method of flow calculation.  Maurice and Jones noted, at equilibrium, the 
fluorescence of the cornea and aqueous humor differed by a factor of 1.2.
11
  In 1993, van Best et 
al. added a second correction factor to account for the fact that the diamond-shaped intersection 
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of the fluorophotometer's excitation and emission beams was larger than the corneal thickness, 
thus underestimating corneal fluorescence.
14
  Called the spatial resolution correction factor 
(kspat.res), this value was represented by the equation: 
   
(5) kspat.res = 1 / (1 – Q x e
Bd
), 
 
where Q =0.9622, B = -1.848, and d is the thickness of the cornea in millimeters.  These 
corrections leave a final equation of: 
 
  (4)  Ko= -A x (1 + [kspat.resVcCc/1.2VaCa]) 
 
After obtaining fluorophotometric values (Cc and Ca) over at least two time points during 
the steady state fluorescein egress, the slope of that decline can be plotted and representative Cc 
and Ca values used to obtain Ko.  Also required are the previously obtained corneal and aqueous 
humor volume values and corneal thickness (which allows for kspat.res calculation).  Ko can then 
be used to calculate aqueous humor flow using the equations: 
 
(6) Flow = KoVa 
 
Using their new technique, Maurice and Jones calculated the human aqueous humor flow 
rate to average 2.5 μl/min with an average aqueous humor turnover rate (Ko) of 0.015 min, or 
1.5%/min.
11
  This number was similar to earlier studies that had been performed with invasive 
techniques on cadaver eyes,
67
 using less advanced fluorophotometry equipment,
16,68
 and with 
more complicated methods developed at a similar period.
53,54
  At the present time, 
fluorophotometry using this method is considered highly accurate for determining aqueous 
humor flow and, as an entirely noninvasive procedure, has allowed for the inclusion of human 
data to an already large pool of animal data.
69
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 Fluorophotometric Results 
Since the development of their technique, the fluorophotometric method established by 
Maurice and Jones has been utilized in hundreds of investigations that have tested various 
aspects of aqueous humor flow.  These studies have confirmed the average aqueous humor flow 
rate in the normal human eye is around 2.5 μl/min.16,43  Taking the next step, investigators have 
also evaluated changes that occur in aqueous flow rate on both a daily and lifelong basis.  
Investigations have revealed normal circadian rhythms diminish aqueous flow by nearly half 
during sleep, although it changes very little over the course of the waking hours.
15,52,70
  It has 
also been found that aqueous humor flow slowly decreases with age (approximately 2-4% per 
decade of life), although the aqueous humor turnover rate actually increases due to a concurrent 
decrease in anterior chamber size.
16,40
 
Though initially developed for human use, fluorophotometry has often been utilized in 
animal models before subjecting humans to the possibly dangerous effects of various 
pharmacologic compounds being tested.  These studies, combined with the volumes of historic 
data from more invasive research, have provided a large base of knowledge for the animal 
species utilized:  rabbits,
17,18,20,21,38,71-73
 primates,
18,32,44-49,73-76
 and cats.
26-30,35,36,38,47,48,67,72,73,76
  
Recently, the continued expansion of veterinary-specific research has also started compiling 
further data on these animals, as well as dogs, one of the more predominant species of interest in 
veterinary medicine.
22,24,77
 
The aqueous humor flow rate in the normal eye has been determined for a handful of 
species, with some species having numerous values available for comparison.  The following 
species have been evaluated via fluorophotometry and the average flow rates are:  cynomolgus 
monkey (1.7 μl/min),18,32,45-49,74,76,78 owl monkey (2.15 μl/min),75 rabbit (3 μl/min),17-21 dog (5 
μl/min),22,24,77 and the cat (6 μl/min).26-29  With a few exceptions, fluorophotometrically 
determined aqueous humor flow values tend to be fairly similar across studies 
performed.
25,73
Unlike in human studies, fluorophotometric comparisons of aqueous flow have 
differed greatly from invasive studies performed in the past, especially in the feline species 
where historic values range from 10-20 μl/min, far above 6 μl/min.30,31,35-38  This difference has 
yet to be explained. 
11 
 
 Intraocular Pressure 
 Tonometry 
Intraocular pressure is created by the balance between the formation of aqueous humor 
and the resistance to aqueous outflow.  Tonometry is the measure of tension or pressure and is 
performed noninvasively to determine the pressure within the eye created by this balance in 
aqueous humor.  The first ocular tonometer was introduced by von Graefe in 1862.
79
  His device 
was a form of indentation tonometry, where direct pressure is placed on the eye, and resistance 
measured.  In 1905, Schiøtz refined the indentation tonometer and his device became the most 
widely used tonometer and is still used today.
79
 
In 1885, Maklakov introduced the first applanation tonometer.
43
  This device utilized a 
suspended block of known weight that was covered in dye; the block was allowed to rest on the 
cornea, which would remove the dye in the area the cornea was flattened to allow contact.  This 
area could then be used to calculate the pressure required to flatten the cornea to the degree 
noted.
80
  Maklakov’s design was improved with the development of the Goldmann tonometer in 
1954.  Attached to a slit lamp, Goldmann’s technique utilized topical fluorescein which, when 
aligned with a corneal contact prism, allows calculation of the force required to applanate a 
known area with great accuracy.
79
  Due to the fixed nature of the tonometer, the requirement for 
the patient to remain still for several seconds, and the inability for the Goldmann tonometer to 
take pressures in diseased and edematous corneas, more practical tonometers have been 
developed.
81
 
With the development of the Mackay-Marg tonometer in 1959, the electronic applanation 
tonometer was born.
81
  This tonometer utilized a ceramic or quartz-actuating rod that is housed 
within a steel probe.
79,81
  As the probe is pressed against the cornea, the rod depressed, activating 
a position transducer that enables the device to calculate pressure.  Though also quite accurate, a 
handheld device similar to the Mackay-Marg device, the TonoPen, was introduced in the late 
1980’s and has largely replaced the Mackay-Marg device due to its portability, position 
independency, and ease of use.
82
  This has been especially true in veterinary medicine, where 
patients are highly mobile and often resistant to IOP measurement.  With this ease of use, does 
come some loss of accuracy, as the TonoPen is known to overestimate IOP at low levels and will 
12 
 
underestimate IOP at high levels; however, these inaccuracies have been deemed clinically 
unimportant.
83
 
Though the concept for a dynamic or rebound tonometer is decades old,
84
 a method for 
clinical use has only recently been introduced.
85,86
  Rebound tonometry relies on a small (1mm) 
round, plastic tipped probe that is expelled from the tonometer electromagnetically.  The probe 
will then bounce off the surface of the cornea and return to its original position.  The machine 
notes the deceleration of the probe and this is translated into a pressure measurement (the faster 
the probe decelerates, the higher the pressure in the eye).
86
  Used in both human and veterinary 
medicine, rebound tonometers are highly portable and do not require topical anesthesia.
79
  
Investigations into many different species have demonstrated they are accurate, comparable to 
other accepted methods of tonometry or invasive manometry, easy to use, and accepted by 
patients of all species.
87-90
 
Various tonometric studies utilizing the techniques described above have established 
normal ranges for IOP for various species:  humans (average 15 mmHg, range 10-21 mmHg),
1,91
 
cats (average 19-22, range 10-30 mmHg),
83,87,92
 and dogs (average 12-21, range 10-25 
mmHg).
4,88,90
   The value of this measurement cannot be underestimated, as it is often our only 
insight into the aqueous humor dynamics of the clinical patient.  An important part of the clinical 
evaluation of ocular disease, it can be used to document abnormal IOPs that occur during various 
disease processes.  Elevated pressures are most often attributed to a disruption of normal aqueous 
outflow, which can occur transiently in the case of post-operative ocular hypertension (a 
common sequela to recent intraocular surgery), or can represent a more permanent and 
devastating condition such as glaucoma.  In the intact globe, low IOPs are caused by decreased 
aqueous humor production.  This can occur as a sequela to old age, active uveitis causing active 
inflammation within the ciliary processes, or chronic uveitis that permanently damaged the 
ciliary body. 
 Physiologic Effects on Intraocular Pressure 
In the assessment of IOP, it is important to consider the various normal physiologic 
processes that can impact IOP measurement.  First and foremost, proper handling and 
positioning of the patient is necessary to ensure accurate readings.  In human medicine, IOPs 
should be taken in a sitting or standing position, whereas felines and canines should be restrained 
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in a sitting, laying, or standing position.
93-95
    Various reports have documented differences in 
IOPs, depending on the position of the head in relation to the body in several species.
93-95
  If 
manual restraint is required, it is also important to avoid the inadvertent increase of IOP by 
placing direct pressure on the globe (digital or by pulling the eyelids tight) or by indirectly 
increasing IOP via jugular vein occlusion.  The stress of the patient should also be considered, as 
the fight or flight response in some animals adds increased pressure on the globe from eyelid or 
extraocular muscle pressure.
4
  Indeed, a recent study showed that IOP slowly decreased over the 
5 minute time period when dogs were held in the same position.
93
  It is plausible to assume that 
the patients involved had become more accustomed to their restraint over that time period.  In a 
research setting, it is exceedingly important that IOP be measured the same way in each patient 
over the course of the study to ensure that all of these factors are constant and do not constitute a 
variable that could bias results.
93
 
Another physiologic effect on IOP to consider is the natural circadian rhythms that have 
been shown to effect pressure levels.  In humans, circadian rhythms have been variably recorded 
and contradicting data has been presented.
71
  The majority of studies have demonstrated a basic 
rhythm exists for IOP, with the peak pressure found during the night.
96-99
  These daily variations 
have been found to influence IOP differently based on the position of the subject, the disease 
status of the eye studied, and even the effects of pharmacologic compounds that alter IOP.
52
  
Similar rhythmic fluctuations in IOP have been noted in other species, which have revealed that 
the peaks and valleys of the rhythmic pressure fluctuations often depend on the time of day the 
animal is most active, with nocturnal animals, such as cats and rabbits, experiencing peak IOPs 
different times of the day than animals who are active during the day, such as cynomolgus 
monkeys.
71,92,100-107
 
 Relation to Aqueous Humor Flow 
As discussed earlier, circadian rhythms have also been documented affecting aqueous 
humor flow.
15,52
  With the continued development of aqueous humor flow studies and the 
seemingly obvious link between flow and IOP, researchers have often concurrently studied them 
together in order to better understand the interaction between the two.  What has so far been 
elucidated is surprising.  In the majority of studies utilizing human subjects, both normal and 
diseased eyes, changes in aqueous humor flow are not necessarily similarly manifested by 
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changes in IOP.  In a study specifically designed to assess the interaction between the two, 
Carlson et al. altered subject body position to increase IOP and simultaneously measure aqueous 
flow using fluorophotometry.
95
  They found significant alteration of IOP, with only mild changes 
in aqueous flow with the highest pressures.  Sit et al. demonstrated in normal eyes that although 
aqueous humor flow decreased by half from day to night (2.26 μl/min to 1.12 μl/min), IOP was 
minimally reduced (18.9 mmHg to 17.8 mmHg).
52
  Similar findings have also been seen in 
research performed on abnormal or diseased eyes.  An evaluation by Yablonski et al. 
demonstrated that no change in fluorophotometric flow was noted, despite significant decreases 
in IOP in patients after trabeculectomy surgery.
108
  A recent review by McLaren summarized the 
data of 20 separate studies investigating eyes of people suffering from systemic or ocular 
disease.  In the study, the aqueous flow was compared to IOP.  The findings indicate that IOP 
and aqueous humor flow are independent of each other, revealing no significant compensatory 
relationship.  Included within this summary were 5 studies investigating the effects of ocular 
hypertension and open-angle glaucoma in humans.
16
 
At first glance, the data reported would seem to contradict our basic conception of how 
IOP is determined.  As stated earlier, IOP is created by the production of the aqueous humor and 
the resistance to its outflow.  If we manipulate the Goldmann equation presented earlier to reflect 
IOP, we see that: 
 
 Pi = (F – US)/C + Pe,  
 
where F = rate of aqueous humor formation, Pi = the IOP, Pe  = the episcleral venous 
pressure, U = uveoscleral outflow and C is the facility of outflow measured tonographically.  
Aqueous humor flow, as determined by fluorophotometry, accounts only for F and U within the 
Goldmann equation.  As discussed earlier, active secretion and resultant diffusion (the main 
components of aqueous humor production, F) and uveoscleral outflow (U) are both considered 
independent of IOP, thus flow measurements would be expected to be independent of pressure.  
It would therefore stand to reason, that changes in IOP seen in the studies listed above were due 
to changes in the facility of outflow and episcleral venous pressure.  It is important to note that 
no in vivo fluorophotometric studies have been performed at excessive IOP or on subjects 
suffering from closed angle glaucoma, the most common type affecting veterinary species. 
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  Pharmacologic Alteration of Aqueous Humor Dynamics 
The study of aqueous humor dynamics has helped researchers to understand the 
intricacies of the aqueous flow pathway in the many species utilized for their investigations.  A 
large part of that body of research focused on various pharmacological compounds designed to 
alter normal dynamics in order to reveal the exact mechanisms involved.  As a side product of 
the use of these compounds, and ultimately the true goal of the research itself, various 
compounds were found that could be used therapeutically in humans and animals that suffered 
from alterations in normal dynamics.   
The compounds investigated vary widely in their effect on the eye, as well as their 
efficacy for altering IOP and aqueous flow.  This has demonstrated the complexity of the 
regulation of aqueous humor dynamics within the eye and the importance in understanding the 
actions of these medications.  A brief review of the compounds found to alter IOP and aqueous 
humor flow (conventional and uveoscleral) can be found below. 
 β-Adrenergic Antagonists 
Propranolol was discovered to reduce IOP when administered systemically in 1967 and 
topically in 1972.
16
  Since that time, several β-blockers have been introduced including 
betaxolol, levobunolol, and timolol.  As this class of medications is one of the most widely used 
in the management of glaucoma in humans,
109
 numerous reports exist, which have revealed these 
compounds reduce IOP and the flow of aqueous humor, suggesting a decrease in aqueous humor 
production was the source of β-blockers’ hypotonic effect.75,92,106,110-114  The exact mechanism is, 
as yet undiscovered, but the traditional view purports β-blockade at the level of the ciliary 
processes alters neuronal control of aqueous humor formation.
113
 
 α2 Adrenergic Antagonists 
Makabe initially discovered the ability for clonidine to lower IOP in 1966.
16
  Para-amino-
clonidine (apraclonidine) was subsequently developed as a topical preparation and was also 
found to reduce IOP.  Later studies, revealed aqueous humor flow was similarly decreased and 
so the presumed method of action was a reduction in aqueous humor production.
115
  It is 
currently postulated that these medications exact their effects by inhibiting norepinephrine 
release at the sympathetic nerve-ciliary body junction.
109
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 Adrenergic Agonists 
The study of adrenergic agonists (primarily epinephrine) effects has provided conflicting 
results, but they are generally considered to reduce both aqueous humor production and increase 
aqueous outflow.
29,40,116
  The ability for this medication class to exert its effects is enhanced 
during the night, when it is believed low levels of endogenous adrenergic hormones are in 
circulation.
40
  Dipivefrin is the lipophilic prodrug of epinephrine that is commercially available 
for clinical use.  Aqueous production is believed to be reduced through decreased blood flow to 
the ciliary body via vasoconstriction.  It is unknown how these medications exert their effect on 
aqueous outflow.
117
 
 Cholinergic Agonists 
Direct-acting compounds such as pilocarpine and carbachol, as well as indirect-acting 
compounds such as demecarium bromide have been shown to decrease IOP and increase 
trabecular outflow facility.
118-121
  Fluorophotometric studies have shown less aqueous humor 
flow effects,
16,40
 and in some cases, the addition of pilocarpine appeared to decrease the efficacy 
of other medications in reducing aqueous humor flow.
122
  The contraction of the ciliary muscle in 
response to stimulation from these compounds is believed be the source of increased outflow.  
This contraction is more effective in humans and other animals with a scleral spur.
109
 
 Prostaglandins and Prostaglandin Analogues 
The prostaglandin and prostaglandin–associated compounds have been the focus of 
extensive research over the last two decades.  This is due in large part to the significant 
reductions in IOP demonstrated through their use.  This research has documented these 
compounds exert their effects through receptor-mediated channels that are highly species-
specific, and derivative compounds that stimulate several receptors are the most effective in 
altering aqueous humor dynamics.
26,32,123-131
  Though a handful of studies have shown mild 
increases in aqueous humor flow, the majority of studies have shown no fluorophotometric 
increase in aqueous flow, instead finding significant increases in the calculated facility of 
uveoscleral outflow, as summarized by Toris in 2008.
124
  This would indicate these compounds 
reduce IOP by increasing uveoscleral outflow and, despite the miosis created, do not 
significantly influence conventional outflow (though increases in trabecular outflow facility have 
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been demonstrated inconsistently).
124
  Several prostaglandin analogue compounds are now 
available for clinical use, including latanoprost (PGF2α), bimatoprost (PGF2α), travoprost 
(PGF2α), and unoprostone (PGF2α).
124
  As all of these compounds specifically target the FP 
prostaglandin receptor (designed to receive PGF2α, they have been demonstrated to be ineffective 
at lowering IOP in cats (who lack FP receptors along the uveoscleral outflow pathway).
123
  Cats 
do have FP receptors associated with their irises and these compounds do lead to miosis in this 
species.
123  
Other compounds currently in or awaiting clinical trials include tafluprost (PGF2α) 
and butaprost (EP2).
32,124
 
 Carbonic Anhydrase Inhibitors 
Carbonic anhydrase catalyzes the reaction that changes carbon dioxide (CO2) and water 
(H2O) into carbonic acid (H2CO3), also helping to dissociate an H
+
 atom, thus creating 
bicarbonate (HCO3
-
).
1
  Carbonic anhydrase has been subcategorized into seven isoenzymes (CA 
I-VII), with various isoenzymes creating bicarbonate ions in many places in the body, including 
the red blood cells, renal tubules, and the ciliary body epithelium.  Bicarbonate is vital in 
maintaining normal homeostatic functions in all three areas, including buffering the blood, 
maintaining normal proximal tubular ion exchange, and contributing to the production of 
aqueous humor.
4
 
Acetazolamide was the first carbonic anhydrase inhibitor (CAI) developed for clinical 
use, and was the initial step toward pharmacologic manipulation of aqueous humor dynamics.  In 
1955, Becker first documented that acetazolamide reduced IOP.
67
  Subsequent studies 
documented reductions in aqueous humor flow, indicating CAIs exerted their effect on IOP at 
the level of aqueous humor production.
132
  Researchers have since discovered carbonic 
anhydrase creates bicarbonate within the epithelial layers of the ciliary processes.  This 
bicarbonate is then excreted into the posterior chamber of the eye along with actively secreted 
Na
+
 ions, which creates an osmotic diffusion gradient that pulls water into the posterior chamber, 
forming a substantial percentage of the aqueous humor volume.
4
  It is also hypothesized that the 
presence of bicarbonate is necessary for normal function of active Na
+
 secretion.
1
  The proposed 
mechanisms by which CAIs reduce the secretion of Na
+
 include:  decreasing the available HCO3
-
 
necessary for direct transport with Na
+
, reducing HCO3
-
 concentration leading to a reduction in 
intracellular pH preventing proper function of Na
+
-K
+
-ATPase, or by decreasing availability of 
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H
+
 used for Na
+
 transport.
1
  CAIs suppress the production of bicarbonate by attaching to the 
carbonic anhydrase enzyme at the site of the carbonic acid receptor using a sulfonamide group, 
thereby preventing carbonic acid attachment.
133
  In the ciliary body epithelium, CA II, III, and IV 
have been demonstrated to be present, and CA II is considered the most important target for 
CAIs.
134
  To be effective 99% of the carbonic anhydrase II enzymes present in the ciliary body 
must be inhibited.
135
 
 Systemic Carbonic Anhydrase Inhibitors 
Acetazolamide has been found to be 40-60% successful in reducing IOP in various 
human studies.
1
  In dogs and cats, it has been proven to be similarly effective.
136
  Unfortunately, 
as a systemically administered medication, important side effects have been noted with the use of 
acetazolamide.  Those side effects include metabolic acidosis, hypokalemia, diuresis, and 
gastrointestinal disturbances.
109
  Not surprisingly, these side effects can be traced back to the 
other regions of carbonic anhydrase activity.  Cats are especially susceptible to these side effects, 
to the point that acetazolamide is no longer recommended for use in this species.
109
  
Methazolamide, another systemic CAI, is more potent than acetazolamide, has been shown to 
exert its effects over a longer time period, and has been demonstrated to be effective in lowering 
IOP.
24,137-139
  For these reasons, it can be administered at lower overall levels allowing for 
patients to experience less severe systemic side effects. 
 Topical Carbonic Anhydrase Inhibitors 
For many years, it was thought that topical formulations of CAIs would not be able to 
reach the 99% saturation required to effectively reduce IOP.
1
  The introduction of dorzolamide 
disproved that theory.  Numerous studies have shown topically applied dorzolamide is effective 
at lowering IOP in various species, as well as reducing aqueous humor flow.
22,103,104,110,140-144
  
Dorzolamide is a topical CAI formulation that is most sensitive for CA II, and has been shown to 
produce blood levels 1/200
th 
the level necessary to see systemic side effects in humans.
135
  This 
makes it an ideal compound to manipulate aqueous production in the ciliary body without 
affecting carbonic anhydrase in other areas of the body, even other CA II present systemically.  
Concurrent administration of dorzolamide and systemic CAIs have shown a similar response to 
systemic CAIs alone, but no additive effect on IOP has been documented.
137,143
  With a pH of 
5.6, ocular irritation upon application is the most common side effect.
109,145
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Chapter 2 - Evaluation of the Aqueous Humor Flow Rate in 
Normal Cats Using Fluorophotometry 
 Introduction 
The flow of aqueous humor is an important aspect of normal ocular health in all animals.  
The function of the eye relies on the normal turnover of aqueous humor in order to provide 
nutrients to and remove waste products from avascular structures within the eye, including the 
corneal endothelium and lens.
1
  Aqueous humor flow is also a vital component in establishing 
normal IOP, which provides the framework for appropriate visual function by maintaining 
structural alignment for the cornea, lens, and retina.
 4
  Alterations in normal aqueous humor flow 
can result from serious ocular diseases, such as glaucoma and uveitis, which can have damaging 
effects on the eye and threaten vision.Though the changes in flow may not be the direct cause of 
these damaging sequelae, a proper understanding of flow during these events may help elucidate 
the specifics of the disease process or enable objective evaluation of potential therapeutic 
interventions. 
 Fluorophotometry is an accurate tool for noninvasive assessment of aqueous humor 
flow.  The first objective fluorophotometer was introduced by Maurice in 1963 and was followed 
three years later by the introduction of a specific mathematical model by Jones and Maurice.
11,55
  
This method estimates the rate of aqueous flow based on a reduction in fluorescence of the 
aqueous humor over time following topical administration of sodium fluorescein.  The model is 
predicated upon the assumption that a steady state is reached as the fluorescein passes from the 
cornea into the aqueous humor and eventually exits via the aqueous outflow tracts.  Decay curves 
of this steady decline are formed using periodic fluorophotometric measurements taken hours 
after initial fluorescein application to the cornea.  The slopes of these decay curves are the basis 
for aqueous flow measurement, once applied to the aforementioned equations.  This model has 
been utilized, with slight modification, in several species including humans,
13,16,40,116,141
 dogs,
22-25
 
and cats
26-29
 and is the predominant model utilized for flow investigations today. 
Fluorophotometric flow studies have been reported in the feline species, though previous 
investigations utilized this information largely as an adjunct to the evaluation of other aspects of 
aqueous humor dynamics. The protocols for these evaluations are varied and often require large 
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numbers of topical drops and long durations between drop application and fluorophotometric 
evaluation.  In these feline studies, the application of the fluorescein, fluorescein concentration, 
and flow measurement protocol varied significantly.  Consequently, reported aqueous humor 
flow values have fallen across a wide range, from 3.5 to 22.5 μl/min.26-29  As the focus of flow 
determination has been on creating a base value to which treatment values can be compared, this 
variability has largely been ignored and has made it  difficult to compare feline values to other 
species.  Recently, a more streamlined fluorescein application protocol was created for the 
canine species.
 23
  Subsequent investigations have since confirmed the viability of this technique.
 
22,24
 In the feline species, a more streamlined protocol would reduce the time necessary to 
perform fluorophotometry as well as eliminate the variables associated with excessive drop 
application and long durations between fluorescein application and flow measurement.  It would 
then be important to demonstrate this protocol successfully met the assumptions required to trust 
the flow data.  The purpose of this study was to evaluate the aqueous humor flow rate of normal 
cats using a method that has proven successful and repeatable in the canine species with the 
intent to compare values between species as well as to previous investigations in the feline 
species. 
 Materials and Methods 
 Animals 
  This study was performed using 20 cats (8 neutered males and 12 intact females) 
weighing between 2.5 and 5.2 kg.  The average age of the cats used in our study was 11 
months.The cats were purchased from various commercial suppliers and provided by the .
a
  A 
full physical examination including complete ophthalmic examination was performed prior to the 
study.  Cats were assessed via slit-lamp biomicroscopy,
 b
 indirect ophthalmoscopy, corneal 
fluorescein staining,
c
 and rebound tonometry.
d
  All cats were determined to be in good health 
with normal ocular examinations prior to inclusion in the study.  The animals were housed 
individually or in pairs throughout the study.  This study adhered to the guidelines of the 
institutional animal care and use committee at Kansas State University. 
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 Fluorophotometry Protocol 
A random number generator was used to randomly assign the cats to 1 of 4 groups with 5 
cats in each group.  Group assignment dictated the day fluorophotometry would be performed.  
The initial group of 5 cats was utilized to assess the feasibility of the proposed fluorophotometry 
protocol.  The 3-drop protocol described by Ward et al. was used to obtain homogenous 
fluorescein introduction into the cornea and anterior chamber:  one drop of 10% sodium 
fluorescein
e
 was applied via a sterile dropper bottle into both eyes and allowed to remain for 5 
minutes; this process was repeated until 3 drops total had been given.
23
  Five minutes after the 
final drop, the eyes, face, and front limbs were thoroughly rinsed to assure no fluorescein stain 
remained that could be reintroduced during grooming.  Cages and bedding were cleaned or 
removed if any obvious fluorescein drops were present.  One hour and fifty-five minutes after the 
rinse, the cats were sedated using intramuscular ketamine
f
 (5 mg/kg) and medetomidine
g
 (0.03 
mg/kg) to facilitate patient positioning   
At 2 hours post-rinse, fluorophotometric readings were taken of both eyes using a 
computerized, scanning fluorophotometer with anterior chamber adapter.
h
  The head and eyes 
were aligned using a small platform, manual restraint, and a plastic eyepiece adaptor designed to 
approximate appropriate eye position for the holder.  Fluorescein concentrations were measured 
in the cornea and mid-central anterior aqueous humor using a scanning ocular fluorophotometer 
fitted with an anterior chamber adapter.  Repeat measurements were taken at 4, 5, 6, 7, 8, 9, and 
10 hours.  Sedation was repeated at reduced doses (usually 0.01-0.015 mg/kg medetomidine 
only) as necessary to achieve the desired state of compliance for patient positioning.  During the 
periods between measurements, patients’ eyes were kept closed with tape to prevent corneal 
desiccation. 
The remaining 3 groups, 15 cats, were evaluated using the same 3-drop protocol.  The 
same technique and sedation protocols were utilized, with the exception that measurements were 
taken at 5, 6, 7, and 8 hours only. 
 Aqueous Flow Rate Calculation 
  For each cat, fluorophotometric scans were evaluated at each time point to determine the 
corneal and aqueous humor fluorescence levels.  The landmarks used for this assessment were 
the apex of the corneal peak and mid-central plateau of the aqueous readings.  These data points 
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were then natural log transformed, plotted, and regression analysis was performed to derive the 
slopes of the two lines (cornea and aqueous humor).  The equations utilized to determine the 
aqueous flow rate were derived by Jones and Maurice and later modified by Yablonski et al. and 
Van Best et al.:  Flow = KoVa .  Where Ko = -A x (1 + [kspat.res. VcCc/1.2 VaCa]), A= average of the 
slopes of the decreasing cornea and aqueous humor fluorescein levels, Vc= corneal volume, Ca= 
anterior chamber volume, Cc = corneal fluorescein concentration, Ca = anterior chamber 
fluorescein concentration, and kspat.res. = a correction factor necessary to compensate for 
underestimation of corneal fluorescence inherent to fluorophotometry measurement.
11,13,14
  This 
underestimation results because the focal diamond created by the fluorophotometer for 
measurement of fluorescein concentration is wider than the thickness of the feline cornea.  
kspat.res. = 1/(1 – Q x e
Bd
), where Q =0.9622, B = -1.848, and d is the thickness of the cornea in 
millimeters.  A value of 0.565 mm has been reported for the corneal thickness in cats less than 1 
year of age and was utilized for d in this study, resulting in kspat.res. = 1.51.
146
  The corneal and 
anterior chamber fluorescein concentrations (Ccand Ca) were obtained from the midpoint of the 
fluorescein decay curves.  Published averages for the feline anterior chamber volume (Va = 820 
μl) and corneal volume (Vc =165 μl) were used.
27
 The denominator value of 1.2 represents a 
second correction factor established by Jones and Maurice designed to account for an inherent 
difference in fluorescence between the cornea and the aqueous humor that is suggested to be 
present in all species.
11
 
 Data Analysis 
Regression analysis of the natural log transformed corneal and aqueous fluorescein 
concentration was utilized to create linear decay curves.  Correlation coefficients were calculated 
to assess the fit of the four time points to the approximated straight line.  The slopes of these 
curves were then compared to ensure they were decreasing in a reasonably parallel fashion.  
Aqueous humor flow rates were calculated for the right, left, and mean of both eyes as described 
above.  A paired t-test was used to compare the results between the right and left eyes.  Eyes 
were excluded from flow calculation if correlation or slope ratio values represented extreme 
outliers (defined as greater than 3 times the interquartile range). 
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 Results 
Evaluation of corneal and aqueous humor fluorescence revealed the topically applied 
sodium fluorescein was homogenously distributed within the cornea and aqueous humor at the 
four-hour time point and beyond in all cats.  Fluorescein concentrations were noted to slowly 
decline after the four-hour time point. 
The calculated correlation coefficients for the logarithmically transformed fluorescein 
concentration data utilized for aqueous humor flow calculation and the slope ratios between the 
regression lines calculated for the cornea and aqueous humor fluorescein concentration levels are 
summarized below in Table 2.1. 
 
Table 2.1  Correlation coefficients and slope ratios calculated for the change in fluorescein 
concentration over time in the cornea and aqueous humor. 
EYE CORNEAL CORRELATION AQUEOUS HUMOR CORRELATION SLOPE RATIO 
Left 0.78 ± 0.23 (0.19-0.97) 0.92 ± 0.12 (0.59-1.00) 1.61 ± 1.1 (0.23-2.19) 
Right 0.85 ± 0.20 (0.15-0.98) 0.90 ± 0.14 (0.56-1.00) 1.13 ± 0.71 (0.28-4.31) 
Both 0.82 ± 0.21 (0.15-0.98) 0.91 ± 0.13 (0.56-1.00) 1.37 ± 0.96 (0.23-4.31) 
Values reported as mean ± s.d. (range) 
 
The aqueous humor flow rate values obtained for normal feline eyes and the 
corresponding anterior chamber turnover rates are summarized in Table 2.2.  No significant 
difference was detected between aqueous humor flow values for the right and left eyes (p = 
0.2005).   
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Table 2.2  Aqueous humor flow rate and anterior chamber turnover rates determined 
fluorophotometrically in clinically normal cats. 
EYE 
AQUEOUS HUMOR FLOW RATE 
(μL/MIN) 
ANTERIOR CHAMBER TURNOVER RATE 
(RAW/MIN) 
Left 5.05 ± 2.06 (1.17-9.89) 0.006 ± 0.003 (0.003-0.012) 
Right 5.62 ± 2.40 (2.56-10.67) 0.007 ± 0.003 (0.001-0.013) 
Both 5.51 ± 2.21 (1.17-10.67) 0.007 ± 0.003 (0.001-0.013) 
Values reported as mean ± s.d. (range) 
 Discussion 
Utilizing the 3-drop protocol for fluorescein application described by Ward et al. and 
established fluorophotometric methods developed by Maurice and Jones, as modified by 
Yablonski et al. and van Best et al., the average baseline feline aqueous humor flow rate is 5.5 
μl/min in normal cats.  This is the first study to utilize this more streamlined protocol for 
fluorescein administration in cats and the only investigation to date to focus solely on the 
determination of normal aqueous flow in this species.  For this reason, it was important to fully 
evaluate the technique to ensure the tenability of the reported results. 
When utilizing fluorophotometry to evaluate flow it is important to ensure certain 
assumptions are met for the mathematical model to be valid.  They are as follows:  a) the 
topically applied fluorescein is homogenously distributed throughout the cornea and aqueous 
humor during the measured time points; b) after the initial fluorescein application, no further 
fluorescein is applied to the cornea; and c) the corneal and aqueous humor fluorescein 
concentrations decrease at the same rate over the course of the measured time points.  In dogs, 
Ward et al. demonstrated these assumptions could be met using the 3-drop protocol.
23
  
Utilization of this same protocol in this study proved to be equally effective in cats.  Initial 
fluorophotometric readings using 5 cats demonstrated that homogenous, steady state fluorescein 
levels in the cornea and aqueous humor were attained by 4 hours (similar to the time point found 
in the canine species).  A steady decline in fluorescein concentration after that time point allowed 
flow measurements to be taken from 5 hours on, enabling flow calculations to be performed in 
the same day.   
25 
 
The correlation coefficients of the corneal and aqueous humor slopes showed high 
correlation between data points and calculated slopes for this study, indicating the slopes 
obtained were a reliable representation of the data points collected and a reasonable 
approximation of the true rate of decline (Table 1).  Much like previous studies in other species, 
these correlation values obtained after natural logarithm transformation again demonstrate this 
decline to be semilogarithmic in nature.  The analysis of slope ratios reveals a reasonably parallel 
rate of decay between the cornea and aqueous humor.  This allows for the assumption that they 
are decreasing at the same rate, fulfilling the necessary requirements to proceed with flow 
calculation using the described equations.
11,13,14
 
The average correlation values and slope ratios determined for cats in this study were not 
as high as previous reports in dogs.  This could be due to differences in the inherent difficulty 
working with the feline species or simple statistical variability that can occur from study to 
study.  Variation between cat eyes existed with some of the eyes having low correlation values or 
slopes that were less than parallel.  Investigations utilizing fluorophotometry commonly 
experience such issues, which can occur due to patient placement, head or ocular movement, or 
issues with fluorescein reintroduction.  Evaluation of our data pool revealed that often one 
reading stood out as possibly spurious, thereby creating a lower overall correlation.  In general, 
the corneal measurements were often the most affected by these “off” measurements.  This is 
attributed to the thin width of the cornea, which makes accurate measurement of the corneal 
concentration more difficult than the large anterior chamber and, thus, especially susceptible to 
motion artifacts from either head or ocular movements.  During the study, sedation was used to 
limit these movements, but it was possible that minor ocular movements went unnoticed during 
data collection and led to inaccurate readings.   
The reported aqueous humor flow rate in cats ranges widely from 3.6-22.7 μl/min.  A 
review of the literature reveals the original, more invasive investigations of flow tend to have 
higher values (estimating flow in cats to be between 14 and 20 μl/min).7,30,35-38  These older 
measurement techniques were often derivations of outflow facility or were performed under 
constant ocular perfusion and thus, are less likely to accurately depict true aqueous flow.  
Fluorophotometry was developed as a direct measure of aqueous humor flow that can be 
performed in a live patient without significant alteration to the natural flow of fluid within the 
eye and is considered the most accurate method of aqueous humor flow determination.  We 
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calculated the average aqueous humor flow in normal cats to be 5.51 ± 2.20 μl/min.  This 
compares favorably to previous fluorophotometric investigations, where the calculated flow rates 
range between 5.0 and 6.33 μl/min.27-29  Examination of the components of flow calculation 
between these studies reveal that similar values are utilized for corneal volume (150-170 μl) and 
aqueous humor volume (700-820 μl), despite different approaches to volume calculation.  The 
anterior chamber turnover rate (Ko) between studies was also similar, ranging from 0.007/min 
(0.7% per minute, the value from this study) to 0.009/min (0.9% per minute).  Interestingly, 
closer examination of another fluorophotometry study by Hayashi et al., reveals a similar Ko of 
0.0075 /min (0.75% per minute) despite a reported flow rate of 3.6 μl/min.26 The anterior 
chamber volume utilized for calculation was 479 μl, likely the source of the gross 
underestimation of aqueous humor flow in that study and was addressed by the authors.   
Utilizing a similar technique, the aqueous humor flow rate in cats (5.51 μl/min) is similar 
to that of dogs (5.22 μl/min).23 This similarity was unexpected.  Due to the large size of the feline 
anterior chamber, 700-800 μl, one would expect the aqueous humor flow rate in cats would be 
much higher than that of a dog, whose anterior chamber has been reported to be around 400 μl.4  
When evaluating the anterior chamber turnover rate (Ko), the contrast between the two species is 
illuminated.  At 0.7% per minute, the cat has a lower rate of aqueous turnover than the dog at 
1.4% per minute, thus a much lower rate of flow per volume.  In other species, these anterior 
chamber turnover rates have been found to be quite variable with humans between 1.25% and 
1.5%,
11-15 
owl monkeys at 1.0%,
75
 cynomolgus monkeys averaging 1.8%,
18,45,47-49,74,76,131
 and 
rabbits measured at 1.9% and 2.1%.
17,19
  In previous publications, it has been postulated that 
aqueous turnover rates were similar due to the similar metabolic needs of internal ocular 
structures between animals.
23
  This assessment was based on the evaluation of dogs, humans, and 
owl monkeys.  With the addition of the feline data, as well as data from other species, the 
average aqueous humor turnover of all these species ranges around 1-2% of the volume of the 
anterior chamber per minute, seeming to support this assertion, especially considering the 
inherent variability present within aqueous humor flow measurement via fluorophotometry.   
It is important to note, however, that, within that range, the average aqueous humor 
turnover rate in cats is half that of dogs and nearly a third of that in rabbits and cynomolgus 
monkeys.  And, although variability exists, the equations utilized for calculation of aqueous flow 
are fairly sensitive to small changes in the rate of aqueous turnover.  When looking across the 
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spectrum of species with data available, a trend seems to be present.  Higher Ko values are 
present in animals with smaller anterior chamber sizes (rabbits, cynomolgus monkeys), lower Ko 
values are present in animals with larger anterior chamber sizes (cats), and the other species with 
medium sized anterior chambers have Ko values that fall in between.  Building upon the idea that 
a basic metabolic requirement is necessary for the mammalian eye, this trend could represent 
modifications made by species with different anterior chamber sizes to either avoid excessively 
high aqueous flow rates (animals with larger anterior chambers) or to maintain a minimum 
aqueous flow rate necessary for proper ocular function (animals with smaller anterior chamber 
sizes). 
Future investigations into the relationship between aqueous humor flow, anterior 
chamber size, globe size, and the metabolic demands of the internal ocular structures of species 
with different anterior chamber sizes are necessary to firmly establish if this trend is relevant or 
simply a product of variability within aqueous flow measurement.  If relevant, these studies 
might also illuminate differences in ocular function that could influence our understanding of 
ocular disease and strategies toward their treatment. 
 Footnotes 
a
 Liberty Research Inc, Waverly, NY; Sinclair Bio Resources LLC, Auxvasse, MO 
b
 Kowa SL-15, Kowa Optimed Inc, Torrance, CA 
c
 Bio GloTM, Rose Stone Enterprises, Alta Loma, CA 
d
 TonoVet®, Tiolat Oy, Helsinki, Finland 
e
 AK-Fluor®10%, Akorn Inc, Lake Forest, Illinois 
f
 Domitor®, Orion Corporation, Espoo, Finland 
g
 VetaKet®,IVX Animal Health Inc, St. Joseph, Missouri 
h
 FM-2 Fluorotron Master, Ocumetrics, Mountain View, CA 
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Chapter 3 - Effects of Topical 2% Dorzolamide Solution on 
Aqueous Humor Flow Rate and Intraocular Pressure in 
Normal Cats 
 Introduction 
Carbonic anhydrase inhibitors are used for the clinical management of glaucoma and 
ocular hypertension in humans and animals.  The enzyme carbonic anhydrase catalyzes the 
reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic 
acid.  Carbonic anhydrase within the ciliary body epithelium produces bicarbonate, which is 
excreted into the posterior chamber of the eye.  This bicarbonate, along with actively secreted 
sodium ions, creates an osmotic diffusion gradient pulling water into the posterior chamber to 
form aqueous humor.
4
  The administration of CAIs suppresses the production of bicarbonate by 
using a sulfonamide group to attach to the carbonic anhydrase enzyme, thereby preventing 
carbonic acid attachment.
133
  In the ciliary body epithelium, carbonic anhydrase  II,
 147
 III,
 4
 and 
possibly IV
148
 have been demonstrated to be present; however, carbonic anhydrase II is 
considered the most important target for CAIs.  In order to decrease IOP, 99% inhibition of 
carbonic anhydrase II is necessary in the ciliary body epithelium.
135
  The administration of oral 
CAIs can be associated with anorexia, gastrointestinal disturbances, increased respiratory rate 
secondary to metabolic acidosis, hypokalemia, blood dyscrasias, and neurologic abnormalities in 
humans and other species.
109,149-151
  Cats appear to be more susceptible to the side effects of oral 
CAIs and these medications should not be used in this species.
109,152
  Due to the adverse effects 
associated with systemic CAIs, topical formulations have been developed.  The current 
commercially available topical ophthalmic CAIs include a 2% dorzolamide hydrochloride 
solution and a 1% brinzolamide suspension. 
Previous studies have documented the IOP lowering effects of topical dorzolamide 
solution in several species.
 22,103,104,153-156
  Topical dorzolamide has also been demonstrated to 
decrease aqueous humor flow in dogs,
22
 rabbits,
153
 and humans.
114,157
  The mechanism of action 
of topical application of 2% dorzolamide solution in humans,
158
 monkeys,
159
 and dogs
22
 is to 
decrease aqueous humor production, but this has not been documented in cats.  We hypothesized 
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that topical application of 2% dorzolamide solution three times daily in clinically normal cats 
would significantly decrease aqueous humor flow rate and IOP.  
 Fluorophotometry is an accurate and noninvasive method for measuring aqueous humor 
flow.
11,13
  Anterior segment fluorophotometry has been used to determine the aqueous humor 
flow rate in clinically normal dogs
23
 and cats (see Chapter 2) and in dogs after topical and 
systemic  administration of CAIs.
22,24
  The purpose of this study was to investigate aqueous 
humor flow rate and IOP following topical application of 2% dorzolamide in normal cats using 
fluorophotometry and rebound tonometry, respectively. 
 Materials and Methods 
 Animals 
Twenty domestic shorthair cats (8 neutered males and 12 intact females) weighing 
between 2.5 and 5.2 kg were used in this study.  The average age of the cats used in our study 
was 11 months.The cats were purchased from various commercial suppliers and provided by the 
Kansas State University Department of Diagnostic Medicine/Pathobiology.
a
  An ophthalmic 
examination including slit lamp biomicroscopy,
b
 fluorescein staining,
c
 rebound tonometry,
d
 and 
indirect ophthalmoscopy
e
 was performed prior to the study.  All of the cats had normal 
ophthalmic and physical examinations prior to inclusion in the study.  The cats were housed in a 
temperature-controlled environment and exposed to an automated 12-hour light/dark cycle (light 
phase from 7AM to 7PM, dark phase from 7PM to 7AM).  This study was approved by the 
Institutional Animal Care and Use Committee at Kansas State University 
 Experimental Design 
During a 1-week acclimation period, IOP was measured three times daily in all cats using 
a rebound tonometer without the aid of a topical anesthetic.  At the initiation of the experiment, 
the cats were randomly divided into a control group (5 cats) and a treatment group (15 cats) 
using a random number generator.  The length of the study was 10 days, divided into a 
pretreatment phase (days 1-3), baseline fluorophotometry measurement (day 4), treatment phase 
(days 5-9), and treatment fluorophotometry measurement (day 10).  IOP was measured at 7AM, 
10AM , 1PM, 5PM, and 9PM  during the pretreatment and treatment phases by a single investigator 
(AJR).  During the treatment phase, the control group received one drop (50 µL) of an artificial 
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tear preparation
f
 in both eyes and the treatment group received one drop (50 µL) of topical 2% 
dorzolamidesolution
g
 in both eyes at 7AM, 3PM, and 11PM.  A final treatment was administered at 
7AM on day 10.  A second investigator (WRC) administered the topical medications to each cat 
from identical, sterile dropper bottles.  
The aqueous humor flow rate was measured using anterior segment fluorophotometry to 
obtain baseline data prior to medication administration and on the final day of the study.  The 
fluorescein administration protocol was similar to that used in previous studies:  one drop (50 
µL) of 10% fluorescein
h
 was applied to each cornea of all cats every 5 minutes until a total of 3 
drops had been given.  Five minutes after the last fluorescein drop was administered, the eyes of 
each cat were rinsed thoroughly to ensure that fluorescein did not remain in the preocular tear 
film.  The forelimb paws and other areas of the body were also rinsed thoroughly to prevent 
fluorescein dye from being reintroduced into the tear film by the cat rubbing its eyes.
22
  
Fluorescein concentrations were measured in the cornea and mid-central anterior chamber, using 
a computerized scanning ocular fluorophotometer
i
 with an anterior chamber adapter.  The cats 
were sedated with a combination of medetomidine
j
 (0.03 mg/kg) and ketamine
k
 (5 mg/kg) 
intramuscularly in order to facilitate proper positioning in front of the fluorophotometer.   The 
scans were performed at 5, 6, 7, and 8 hours after fluorescein administration.  
 Aqueous Flow Rate Calculation 
At each time point the corneal and aqueous humor fluorescein concentrations were 
determined.  The fluorescein concentrations (ng/ml) were natural log transformed, plotted, and 
regression analysis was performed to derive the slope.  The equations used to determine the 
aqueous humor flow rate were:  Flow = KoVa .  Where Ko = -A x (1 + [kspat.res. VcCc/1.2 VaCa]), A 
= average of the slopes of the decreasing cornea and aqueous humor fluorescein levels, Vc= 
corneal volume, Va= anterior chamber volume, Cc = corneal fluorescein concentration, Ca = 
anterior chamber fluorescein concentration, and kspat.res. = a correction factor necessary to 
compensate for underestimation of corneal fluorescence inherent to fluorophotometry 
measurements.
11,13,14
This underestimation results because the focal diamond created by the 
fluorophotometer for measurement of fluorescein concentration is wider than the thickness of the 
feline cornea.kspat.res. = 1/(1 – Q x e
Bd
), where Q =0.9622, B = -1.848, and d is the thickness of the 
cornea in millimeters.  A value of 0.565 mm has been reported for the corneal thickness in cats 
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less than 1 year of age and was utilized for d in this study, resulting in kspat.res. = 1.51.
146
  
Published values for the feline anterior chamber volume (Va = 820 μl) and corneal volume (Vc 
=165 μl) were used.27  The denominator value of 1.2 represents a second correction factor 
designed to account for an inherent difference in fluorescence between the cornea and the 
aqueous humor.
11
 
 Data Analysis 
Regression analysis of the natural log transformed corneal and aqueous fluorescein 
concentration was utilized to create linear decay curves.  Correlation coefficients were calculated 
to assess the fit of the four time points to the approximated straight line.  The slopes of these 
curves were then compared to ensure they were decreasing in a reasonably parallel fashion.  Eyes 
were excluded from flow calculation if correlation or slope ratio values represented extreme 
outliers (defined as greater than three times the interquartile range).  Aqueous humor flow rates 
were calculated for all eyes both before and during the assigned treatment.  A repeated measures 
ANOVA was used to compare aqueous humor flow rates before and during treatment in the 
dorzolamide and control groups.  IOP measurements before and during treatment in the control 
and dorzolamide groups were analyzed using a hierarchical linear mixed-model ANOVA with 
repeated measures and a Tukey-Kramer adjustment.  IOPs were also analyzed using a repeated 
measures ANOVA with a Tukey-Kramer adjustment for multiple comparisons to evaluate time-
matched IOPs before and after treatment in both the control and dorzolamide groups at each 
measurement time point.  Statistical significance was set at a P ≤ 0.05. 
 Results 
The calculated correlation coefficients and slope ratios for the logarithmically 
transformed fluorescein concentration data utilized for aqueous humor flow calculation (for the 
cornea and aqueous humor) were acceptable, indicating the calculated aqueous humor flow 
values are accurate. 
The average aqueous humor flow rate for normal cats prior to treatment was 5.90 ± 2.2 
μl/min in the dorzolamide group and 4.27 ± 1.8 μl/min in the control group.  There was no 
statistically significant difference between the two groups (P = 0.1308).  Aqueous humor flow 
values after treatment for the dorzolamide and control groups were 3.47 ± 1.5 μl/min and 4.53 ± 
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1.1 μl/min, respectively.  The difference between aqueous humor flow values before and after 
treatment was statistically significant for the dorzolamide group (P = 0.0002) and was not 
significant for the control group (P = 0.9922).  These findings are summarized in Figure 3.1.  
The average decrease in aqueous humor flow in normal cats receiving topical 2% dorzolamide 
was 2.43 μl/min, a decrease of 41%. 
 
Figure 3.1  Aqueous Humor Flow:  Before and During Treatment 
 *P = 0.0002 
 
The average IOP for normal cats prior to treatment was 14.9 ± 1.0 mmHg in the 
dorzolamide group and 15.5 ± 1.1 mmHg in the control group.  There was no statistically 
significant difference between the two groups (P = 0.9288).  IOP values after treatment for the 
dorzolamide and treatment groups were 11.1 ± 1.0 mmHg and 15 ± 1.0 mmHg.  The difference 
between IOP before and after treatment was statistically significant for the dorzolamide group (P 
< 0.0001) and was not significant for the control group (P = 0.7198).  These findings are 
summarized in Figure 3.2.  The average decrease in IOP in normal cats receiving topical 2% 
dorzolamide was 3.9 mmHg, a decrease of 26%.IOPs were noted to be significantly reduced at 
all time points in dorzolamide treated cats when compared to their baseline values (P < 0.0001).  
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No statistical significance was seen at any time point in the control group (P ≥ 0.9680).  These 
findings are summarized in Figure 3.3. 
 
Figure 3.2  Intraocular Pressure (Averaged):  Before and During Treatment 
 *P < 0.0001 
Figure 3.3  Intraocular Pressure (Time-Matched):  Before and During Treatment 
 *P < 0.0001 
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 Discussion 
Fluorophotometry estimates the aqueous humor flow rate based on serial measurements 
of corneal and aqueous humor fluorescein concentrations following corneal fluorescein loading.  
The fluorophotometer is essentially a modified slit lamp with a fiber optic probe that emits a 
focused beam of blue (480 nm) light.  A barrier filter allows only the green (520 nm) light that 
indicates peak fluorescence to be evaluated, thereby reducing the effect of scatter.  The digital 
radiometer then compares the emitted fluorescein to known fluorescein curves to determine the 
concentration seen at each measurement point.
66
  The decline of fluorescein concentration over 
time is attributed to drainage of the fluorescein-aqueous mix and further dilution as it is replaced 
by new aqueous humor that is being produced.     
The results of this study document that topical 2% dorzolamide administered to normal 
cats three times daily reduced aqueous humor flow by 2.63 µl/min, which corresponds to a 41% 
reduction.  The reduction in aqueous humor flow in the cats in this study is similar to the results 
in normal dogs (43%)
22
 and monkeys (29%),
160\\59
  and higher than the values reported for rabbits 
(17%)
153
 and humans (13-19%).
114,157,160
  In the rabbit study,
153
 one drop of 2% dorzolamide was 
administered only once 2 hours prior to fluorophotometry, which may account for the less 
dramatic reduction in aqueous humor flow compared with the other studies.  A wide variability 
in aqueous humor flow rates has been reported in ocularly normotensive humans with reported 
ranges of 0.2 to 32 µl/min,
161
 1.5 to 4.6  µl/min,
12
 and 1.61 to 5.27 µl/min.
 162
  In dogs, variability 
in baseline aqueous humor flow rate has also been reported with ranges of 2.2-9.8 µl/min
22
 and 
1.47 to 10.69 µl/min.
23
  Similarly, in our study there was a range of baseline aqueous humor flow 
rates from 1.17 to 10.67 µl/min.  Despite the variability noted in aqueous humor flow rates, the 
difference in baseline aqueous humor flow rate for the dorzolamide group (5.90 + 2.2 µl/min) 
and the control group (4.27 + 1.8 µl/min) was not statistically significant.   
Intraocular pressure was measured in this study using a rebound tonometer,
c
 which 
estimates the IOP based on the deceleration of the probe as it rebounds from the corneal surface.  
The tonometer has an internal calibration curve for small animals (dogs and cats).  In a recent 
study the rebound tonometer was compared with direct manometry and applanation tonometry in 
enucleated feline eyes.
87
  The rebound tonometer correlated well with direct manometry in the 
25-50 mmHg range.  The mean IOP in clinically normal cats has been reported to be 20.74 
mmHg (range 11-33mmHg) using the rebound tonometer.
87
  Topical anesthetic was not used to 
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obtain IOP readings in this study.  The use of topical anesthetic with the rebound tonometer did 
not significantly affect the IOP readings in normal cats
87
 and dogs.
88
  The mean pretreatment IOP 
values for both groups (14.9 and 15.4 mmHg) were within the reported normal range for cats 
using the rebound tonometer. 
Topical administration of 2% dorzolamide three times daily for five days in normotensive 
cats caused an average decrease in IOP of 3.9 mmHg compared to pretreatment values, which 
corresponds to a 26% decrease.  In the dorzolamide treated group the IOP at all 5 of the time 
points was significantly different from the pretreatment values (P< 0.0001).  In the control group 
there was no statistically significant difference in IOP at any of the time points evaluated 
compared to pretreatment values (P> 0.97).  Previous studies evaluating the effects of topically 
administered 2% dorzolamide solution in normotensive cats also demonstrated a statistically 
significant decrease in IOP.  Twice daily administration of 2% dorzolamide in normotensive cats 
for 5 days resulted in a 2.9 mmHg (24.2%) decrease in IOP.
104
   Another recent study also 
documented a statistically significant decrease in IOP  in normal cats treated with topical 2% 
dorzolamide either twice daily (1.6 mmHg or 8.8%) or three times daily (2.2 mmHg or 
12.1%).
103
  Concomitant administration of 2% dorzolamide and 0.5 % timolol twice daily in that 
same study did not decrease the IOP greater than the three times daily administration of 
dorzolamide alone.  The time points for intraocular pressure measurement were selected to allow 
for direct comparison to these previously published studies investigating the effect of topical 2% 
dorzolamide on feline IOP.  In comparison, the application of 2% dorzolamide to normotensive 
eyes reduced IOP by 11% in monkeys,
159
 8.5-13%  in humans,
113,140
 and by 24.3% in dogs.
22
 
The magnitude of the effect of dorzolamide on IOPs in normotensive cats may not be an 
accurate representation of the effect of this medication on cats with glaucoma.  Dogs with 
glaucoma typically have a greater decrease in IOP compared to normotensive dogs when treated 
with topical and systemically administered CAIs.
139,163
  A recent study demonstrated a dramatic 
decrease in IOP in cats with primary congenital glaucoma that were treated three times daily 
with topical 2% dorzolamide solution.
156
  In that study, IOP decreased 16.8 mmHg in the left eye 
and 14 mmHg in the right eye, and the diurnal elevations in IOP were also diminished. 
Our study suggests that the mechanism of action of topical 2% dorzolamide solution in 
normotensive cats is the suppression of aqueous humor production on the basis of decreases in 
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aqueous humor flow rate and IOP.  Topical 2% dorzolamide may be a useful drug in treating cats 
with glaucoma or ocular hypertension. 
 Footnotes 
a
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b
 SL-14 Biomicroscope, Kowa Company, Ltd, Tokyo, Japan 
c
 BioGlo™ HUB Pharmaceuticals LLC, Rancho Cucamonga, California 
d 
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f
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